ArticleClinical pharmacokinetics2026
Design Optimization for Developing Population Pharmacokinetic Models in Critically Ill Children: Application to Teicoplanin, Piperacillin and Meropenem.
Article in Clinical pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivePopulation pharmacokinetic (popPK) models in pediatric patients are essential to optimize dosing and ensure therapeutic efficacy. However, study designs are often not fully optimized, leaving room to improve efficiency, which is an important goal in this population, where patients are limited and resources scarce. The aim of the present work is to optimize study designs for the development of popPK models for teicoplanin, piperacillin and meropenem in pediatric patients, with or without continuous kidney replacement therapy (CKRT), to achieve greater model precision while reducing patient burden and economic cost.
methodsMethodology based on the optimization of the Fisher information matrix (FIM) was followed, using the $DESIGN option in NONMEM 7.5. A previously developed model was selected for each of the antibiotics. The number of subjects in the optimized designs was fixed to 28 patients (14 with and 14 without CKRT). It was assumed that only plasma samples were extracted from patients without CKRT, while prefilter, postfilter, and effluent samples could be extracted simultaneously from patients undergoing CKRT. Sensitivity to different proportions of patients with and without CKRT was tested. The optimized designs were evaluated through simulation and re-estimation procedures, including the impact of covariates.
resultsThe number of sampling times per individual needed to achieve precise parameter estimates was 3 in teicoplanin, 4 in piperacillin, and 6 in meropenem. The optimized designs reduced the total number of samples per patient by 25, 51, and 21% for teicoplanin, piperacillin, and meropenem, respectively, compared with the original studies used in the previous studies. The resulting samples were taken during 0-40 h from the beginning of the study in teicoplanin and piperacillin, while in the case of meropenem optimal sampling times went between 0-64 h. The optimized designs remained robust under different proportions of patients with and without CKRT and under different covariate values.
conclusionsThis work emphasizes the importance of optimizing study designs to improve accuracy and precision in the model parameters while reducing the number of samples needed. This is a relevant advantage especially when dealing with critically ill pediatric patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.